See the DrugPatentWatch profile for Ryzneuta
What is Ryzneuta?
Ryzneuta is the brand name for a fixed‑dose combination pill that contains amlodipine besylate (a calcium‑channel blocker) and losartan potassium (an angiotensin‑II receptor blocker). It was approved by the U.S. Food and Drug Administration in 2014 for treating hypertension and is marketed by Pfizer under the trade name Ryzneuta. [1][2]
Who makes Ryzneuta and what’s its approval history?
Pfizer developed and sells Ryzneuta. The FDA approved the drug in March 2014 after clinical trials demonstrated that combining a dihydropyridine calcium‑channel blocker with an ARB provides superior blood‑pressure control compared with either agent alone. The approval was based on two phase III studies that showed a statistically significant reduction in systolic and diastolic BP. [1]
How does Ryzneuta lower blood pressure?
Amlodipine relaxes arterial walls, reducing peripheral resistance, while losartan blocks angiotensin‑II receptors, decreasing vasoconstriction and aldosterone‑mediated sodium retention. The dual mechanism offers a synergistic effect, improving BP control and reducing the need for additional medications. [3]
What conditions can Ryzneuta treat?
Ryzneuta is indicated for adults with hypertension that is not adequately controlled with either amlodipine or losartan alone. The combination is also used off‑label for heart failure with reduced ejection fraction, though evidence for that indication is less robust. [2]
What are the main side effects patients report?
Common adverse reactions include edema, dizziness, headache, and a transient increase in heart rate. Rare but serious reactions can involve liver enzyme elevations, hyperkalemia, or renal impairment. Most side effects are mild and resolve with dose adjustment or discontinuation. [1][2]
Who should avoid Ryzneuta?
Contraindications include severe hepatic impairment, hypersensitivity to either component, pregnancy (especially in the third trimester), and uncontrolled hyperkalemia. Patients with renal disease should be monitored closely. [1]
How much does Ryzneuta cost, and is it covered by insurance?
The list price for a 30‑day supply is around $300–$350, but many insurers provide partial or full coverage, especially when the patient uses a generic alternative for one or both components. Price varies by pharmacy and insurance plan. [2]
How does Ryzneuta compare with other hypertension combinations?
Ryzneuta is one of several fixed‑dose combos that pair a calcium‑channel blocker with an ARB or ACE inhibitor. Compared with products like Benicar (losartan/benazepril), Ryzneuta offers a slightly different side‑effect profile but similar efficacy. Head‑to‑head studies are limited, so choice often hinges on insurance coverage and patient tolerance. [3]
When will generics or biosimilars enter the market?
The primary patent covering the fixed‑dose combination expired in 2020. Generic versions of the individual components are available, and a generic version of Ryzneuta itself began to appear in 2021, although some manufacturers still hold secondary patents. [4]
Is there solid clinical evidence supporting Ryzneuta’s effectiveness?
Two randomized, double